Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn:
“Opportunities and challenges of targeting cGAS–STING in cancer
The cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS)–stimulator of interferon genes (STING) pathway has a crucial role in detecting tumour-derived DNA, whether the pathway is generated spontaneously or induced therapeutically. Activation of the cGAS–STING pathway triggers type I interferon signalling and pro-inflammatory responses in both tumour and immune cells, establishing a delicate balance between pathological inflammation and protective immune responses.
Although preclinical studies have highlighted the promise of targeting the cGAS–STING pathway to enhance antitumour immunotherapy, clinical results have fallen short of expectations. In this Review, we outline key advances in understanding the tumour-promoting and tumour-suppressive effects mediated by the cGAS–STING pathway and discuss opportunities and challenges for its integration into future cancer immunotherapy.
STING agonists in clinical trials
The development of STING agonists for cancer therapy represents a highly competitive area in the pharmaceutical industry. Thousands of compounds have been disclosed in patents, of which approximately 15 have progressed to clinical trials so far.”
Title: Opportunities and challenges of targeting cGAS–STING in cancer
Authors: Changzheng Lu, Wenyan Wang, Yang-Xin Fu
Read the Full Article.
Other articles about Hung Trinh on OncoDaily.